CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.
复制标题
DOI：
10.1016/j.lungcan.2021.05.004
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
Adusumilli PS
中科院分区：
文献类型：
--
作者：
Chintala NK;Restle D;Quach H;Saini J;Bellis R;Offin M;Beattie J;Adusumilli PS
The aim of adoptive T-cell therapy is to promote tumor-infiltrating immune cells following the transfer of either tumor-harvested or genetically engineered T lymphocytes. A new chapter in adoptive T-cell therapy began with the success of chimeric antigen receptor (CAR) T-cell therapy. T cells harvested from peripheral blood are transduced with genetically engineered CARs that render the ability to recognize cancer cell-surface antigen and lyse cancer cells. The successes in CAR T-cell therapy for B-cell leukemia and lymphoma have led to efforts to expand this therapy to solid tumors. Herein, we discuss the rationale behind the preclinical development and clinical trials of T-cell therapies in patients with malignant pleural mesothelioma. Furthermore, we highlight the ongoing investigation of combination immunotherapy strategies to synergistically potentiate endogenous as well as adoptively transferred immunity.
登录
查看更多内容
影响因子：
3.7
作者：
Asai H;Fujiwara H;An J;Ochi T;Miyazaki Y;Nagai K;Okamoto S;Mineno J;Kuzushima K;Shiku H;Inoue H;Yasukawa M
通讯作者：
Yasukawa M
T细胞共刺激和共抑制的分子机制。
DOI：
10.1038/nri3405
发表时间：
2013-04
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
通讯作者：
--
影响因子：
17.1
作者：
Brentjens RJ;Davila ML;Riviere I;Park J;Wang X;Cowell LG;Bartido S;Stefanski J;Taylor C;Olszewska M;Borquez-Ojeda O;Qu J;Wasielewska T;He Q;Bernal Y;Rijo IV;Hedvat C;Kobos R;Curran K;Steinherz P;Jurcic J;Rosenblat T;Maslak P;Frattini M;Sadelain M
通讯作者：
Sadelain M
影响因子：
45.3
作者：
Ahmed, Nabil;Brawley, Vita S.;Gottschalk, Stephen
通讯作者：
Gottschalk, Stephen
影响因子：
11.5
作者：
Chen, Yuhui;Sun, Chuang;Savoldo, Barbara
通讯作者：
Savoldo, Barbara